0K9H Stock Chart & Stats
€5.23
€0.02(0.63%)
At close: 4:00 PM EST
€5.23
€0.02(0.63%)
Day’s Range― - ―
52-Week Range€4.13 - €5.48
Previous CloseN/A
Volume9.42K
Average Volume (3M)3.41K
Market Cap
€1.42B
Enterprise Value€1.70K
Total Cash (Recent Filing)€136.78M
Total Debt (Recent Filing)€396.85M
Price to Earnings (P/E)10.5
Beta0.50
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding316,223,940
10 Day Avg. Volume1,797
30 Day Avg. Volume3,412
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)2.16
Price to Sales (P/S)2.63
P/FCF Ratio25.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.32
Revenue Forecast (FY)€758.51M
Bulls Say, Bears Say
Bulls Say
Historical ProfitabilityFaes Farma has demonstrated substantial earnings power across several years, providing a durable operating base. Although profitability weakened in 2025, the historical record supports the resilience of its branded pharmaceutical and healthcare portfolio.
Strong Equity BaseA sizable equity base gives Faes Farma financial support and reduces dependence on external funding compared with a highly leveraged business. This provides capacity to sustain operations and invest in its pharmaceutical portfolio despite reduced flexibility.
Established Cash GenerationThe company has generally converted its pharmaceutical operations into positive operating and free cash flow, supporting reinvestment and financial obligations. While recent conversion weakened, the multi-year record indicates an underlying ability to generate cash.
Bears Say
Revenue DeclineThe 2025 revenue contraction signals weaker demand, product mix, or market execution after a period of steadier growth. If sustained, lower sales would limit operating leverage and make it harder to fund portfolio development and expansion.
Margin CompressionSharp margin pressure reduces the earnings contribution from each unit of sales and can weaken the company’s ability to absorb cost increases. Persistent compression would challenge the profitability of Faes Farma’s product portfolio.
Higher Leverage And Weaker Cash ConversionThe simultaneous increase in leverage and decline in free cash flow reduces financial flexibility versus Faes Farma’s historically conservative profile. Weaker cash conversion may constrain investment capacity and increase sensitivity to operating setbacks.
Faes Farma News
0K9H FAQ
What was Faes Farma SA’s price range in the past 12 months?
Faes Farma SA lowest share price was €4.13 and its highest was €5.48 in the past 12 months.
What is Faes Farma SA’s market cap?
Faes Farma SA’s market cap is €1.42B.
When is Faes Farma SA’s upcoming earnings report date?
Faes Farma SA’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were Faes Farma SA’s earnings last quarter?
Faes Farma SA released its earnings results on Jul 30, 2026. The company reported €0.183 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Faes Farma SA overvalued?
According to Wall Street analysts Faes Farma SA’s price is currently Overvalued.
Does Faes Farma SA pay dividends?
Faes Farma SA does not currently pay dividends.
What is Faes Farma SA’s EPS estimate?
Faes Farma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Faes Farma SA have?
Faes Farma SA has 316,223,940 shares outstanding.
What happened to Faes Farma SA’s price movement after its last earnings report?
Faes Farma SA reported an EPS of €0.183 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.441%.
Which hedge fund is a major shareholder of Faes Farma SA?
Currently, no hedge funds are holding shares in GB:0K9H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faes Farma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.48%
12-Months-Change
Fundamentals
Return on Equity
4.91%
Trailing 12-Months
Asset Growth
44.17%
Trailing 12-Months
Company Description
Faes Farma SA
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Technical Analysis
Almirall
―
Grifols
―
LABORATORIO REIG JOFRE
―
Compania de Distribucion Integral Logista Holdings
―
Naturhouse Health
―








